Actelion's novel CRTH2 antagonist meets primary endpoint in Phase II study in patients with seasonal allergic rhinitis

25-May-2011 - Switzerland

Actelion Ltd announced that a Phase II study with its novel orally-active CRTH2 antagonist in seasonal allergic rhinitis has met its primary endpoint with statistical significance (p<0.05).

The study assessed the efficacy and tolerability of various doses of this novel CRTH2 antagonist in adult patients with seasonal allergic rhinitis ("hay fever") due to mountain cedar pollen. Treatment in this study was well tolerated across all treatment groups and no serious adverse events were reported.

Jean-Paul Clozel, M.D. and Chief Executive Officer of Actelion commented: "We are very pleased with the results of this study since, for the first time, we now have proof that CRTH2 antagonists can bring clinically relevant benefit to patients suffering from allergic rhinitis. This study complements the positive proof-of-mechanism study in asthma reported in 2009. Together, these studies provide substantial information that will guide us in the further development of this compound and our follow-up molecules in allergic disorders."

Jean-Paul concluded: "We will now fully analyze the data and plan our next steps, taking into account the ongoing development program in asthma. We are very confident that, with these promising results, CRTH2 antagonists can play an important role in expanding Actelion's portfolio beyond specialty products."

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance